Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 23

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 23
---
 working capital and general corporate purposes. We may
require additional capital to conduct clinical trials, expand the commercialization of our existing product and services and to develop
new products and services. In addition, our operating plans may change as a result of many factors that may currently be unknown to us,
and we may need to seek additional funds sooner than planned.

The amount of funding we may
need will depend on many factors, including:

| ● | the revenue generated by our products; |

| ● | the costs, timing and risks of delay of regulatory approvals; |

| ● | the expenses we incur in manufacturing, developing, selling and marketing our products; |

| ● | our ability to scale our manufacturing operations to meet demand for our current and any future products; |

| ● | the costs to produce our continuous glucose monitoring systems; |

| ● | the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property 
 rights;                                                                                                     |

| ● | the rate of progress and cost of our clinical trials and other development activities; |

| ● | the success of our research and development efforts; |

| ● | the emergence of competing or complementary technologies; |

| ● | the terms and timing of any collaborative, licensing and other arrangements that we may establish; |

| ● | the cost of ongoing compliance with legal and regulatory requirements, and third-party payors’ policies; |

| ● | the cost of obtaining and maintaining regulatory or payor clearance or approval for our current or future 
 products including those integrated with other companies’ products; and                                   |

| ● | the acquisition of business, products and technologies, although we currently have no commitments or agreements 
 relating to any of these types of transactions.                                                                 |

If adequate funds are not available,
we may not be able to commercialize our products at the rate we desire and/or we may have to delay the development or commercialization
of our products or license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize.
We also may have to reduce sales, marketing, customer support or other resources devoted to our products. Any of these factors could harm
our business and financial condition.

The clinical trial process is lengthy and expensive with uncertain outcomes. Results of earlier studies may not be predictive of future clinical trial results, or the safety or efficacy profile for such products.

We may not sell any of
our products in any jurisdiction until we have obtained marketing authorization in such jurisdiction. None of our products are
approved for commercial sale in